"a future introduction" is correct and can be used in written English.
You can use it when referencing an introduction that will take place at a later time. For example: "I look forward to our future introduction."
Mr Thomas said Plaid was still opposed to any future introduction of primary school banding as it was "destructive and unreliable".
In a post published Tuesday, users (particularly one called Gerry-Mandarin) decided to come up with a few appropriate titles that could and should be used in all future introductions.
Table 2 p values for Test 1 p value Conclusion Having access to the internet 0.00 Having a certified quality management system 0.00 Introduction of a new product/service 0.00 Intention for future introduction of a new product/service or an organizational innovation/technology 0.00 Getting subsidies 0.00 P1 < P2 everywhere!
Baseline genetic data of pre-release populations is needed to evaluate the effect of these and any future introductions on genetic diversity levels within the wild populations.
Although dabigatran etexilate was shown to be cost-effective compared to the use of "trial-like" generic warfarin (ICER = CAN$10,440/quality-adjusted life year), Sorensen et al fixed the daily drug cost of dabigatran etexilate at CAN$3.20, thereby ignoring the future introduction of a lower-cost generic version of dabigatran etexilate.
However, within economic evaluations comparing a new patented drug to a generic comparator drug which omit the potential future introduction of lower-cost generic versions of the new drug, the ICER will likely be overestimated.
Shih et al had originally claimed that ignoring the future introduction of generic versions of a drug when both the new and comparator drugs are patented drugs would tend to underestimate the ICER. 2 However, we have shown that ignoring this parameter will only result in an underestimation of the ICER under specific conditions (ie, Equation 10).
22– 24 However, in cases where this assumption would not hold, 25, 26 a traditional economic model (ie, one which ignores the future introduction of lower-cost generics) should be favored.
Next, we present the impact of failing to account for the future introduction of lower-cost generic versions of a new drug on the results of a previously published Canadian economic evaluation.
The objective of this paper is to examine the impact of failing to account for the future introduction of lower-cost generic versions of a new patented drug in hopes that it would be included by health economists within future economic evaluations to more accurately reflect the lifetime cost of both treatments.
First, we highlight how failing to account for the future introduction of lower-cost generic versions of a new drug may overestimate its total lifetime cost by means of a mathematical proof and further examine which parameters will influence its impact.
